IRB Number
|
#25234
|
| Description |
The study will evaluate the
effects of doxycycline verses placebo in patients with severe non-proliferative
diabetic retinopathy or early proliferative retinopathy over a 24 month
period. The study objectives are to investigate whether doxycycline can 1)
slow the deterioration or improve retinal function and 2) induce regression,
or slow progression, of diabetic retinopathy. |
| What is expected of me? |
Participants will have complete
eye examinations, including visual field testing and ocular imaging studies,
and blood work at specified study visits. |
| Inclusion Criteria |
Participants need to be >18 years of age, have type 1
or type 2 diabetes mellitus, have a corrected visual acuity of 20/100 or
better in study eye and have severe non-proliferative or mild to
moderate proliferative diabetic retinopathy in at least one eye to be
eligible for this study.
|
| Exclusion Criteria |
Participants with unstable medical status, blood pressure ≥180/110mmHg,
pregnancy, history of major eye surgery within the last 6 months or
high-risk neovascularization are not eligible to participate. |
| Length of Study |
24 months |
| Study Location |
Penn State Hershey Eye Center,
Department of Ophthalmology, Ophthalmology Clinical Trials Center, UPC1 |
| Investigator Information |
Ingrid U. Scott, MD, MPH
Department of Ophthalmology |
| To obtain more information about this study please contact: |
Mary Wilmarth, COMT
717-531-6779
mwilmarth@hmc.psu.edu |
